Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-HL-20-022

Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

Closed on August 11, 2021.

Posted
September 9, 2019
Close date
August 11, 2021
Activity codes
R33
Institutes taking part
NHLBI

The notices it replaced

Its page names no earlier notice: it is new, or it does not say.

Replaced by RFA-HL-23-010.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
11
11 new
Median first-year cost
$460,967
$5,103,677 in all
Institutions
11
11 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. ALBERT EINSTEIN COLLEGE OF MEDICINE1
  2. BRIGHAM AND WOMEN'S HOSPITAL1
  3. HUGO W. MOSER RES INST KENNEDY KRIEGER1
  4. PENNSYLVANIA STATE UNIVERSITY, THE1
  5. STATE UNIVERSITY OF NEW YORK AT BUFFALO1

and 6 other institutions

Most frequent study sections

  1. Special Emphasis Panel (ZHL1 CSR-O (F1))3
  2. Special Emphasis Panel (ZHL1 CSR-O (M2))3
  3. Special Emphasis Panel (ZHL1 CSR-O (F2))2
  4. Special Emphasis Panel (ZHL1 CSR-O (O1))2
  5. Special Emphasis Panel (ZHL1 CSR-O (O2))1
11 awards under RFA-HL-20-022 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2022The genetically engineered pig heart as a bridge to allotransplantation in infants1R33HL163718-01Cleveland, David CUNIVERSITY OF ALABAMA AT BIRMINGHAM, ALFirst-year cost $488,333Study section ZHL1
FY2022MPI/MRI bimodal imaging for non-invasive tracking of extracellular vesicles targeted to infarcted myocardium1R33HL161756-01Liu, GuanshuHUGO W. MOSER RES INST KENNEDY KRIEGER, MDFirst-year cost $487,071Study section ZHL1
FY2022Hyperpolarized Carbon-13 Metabolic MRI of the Human Heart1R33HL161816-01Abraham, Maria RoselleLarson, Peder Eric ZufallUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CAFirst-year cost $482,538Study section ZHL1
FY2022Beat-to-Beat Blood Pressure Monitoring During Sleep1R33HL163749-01Kim, JoshuaVENA VITALS, INC., CAFirst-year cost $415,577Study section ZHL1
FY2022An Enabling Technology for Human Cardiomyocyte Manufacturing1R33HL163711-01Lei, YuguoPENNSYLVANIA STATE UNIVERSITY, THE, PAFirst-year cost $413,610Study section ZHL1
FY2021Exhaled small RNA biomarkers to detect and monitor airway disease1R33HL156279-01Loudig, OlivierSpivack, Simon DALBERT EINSTEIN COLLEGE OF MEDICINE, NYFirst-year cost $532,716Study section ZHL1
FY2021Dynamic tissue-specific modulation of redox stress using chemogenetics1R33HL157918-01Michel, ThomasBRIGHAM AND WOMEN'S HOSPITAL, MAFirst-year cost $513,644Study section ZHL1
FY2021Developing EPR tools for preclinical interrogation of redox regulation mechanisms contributing to acute lung injury1R33HL157907-01Eaton, Sandra S.Nozik, Eva S.UNIVERSITY OF COLORADO DENVER, COFirst-year cost $409,657Study section ZHL1
FY2020An inflammation-induced fibrosis-on-chip system for the testing of anti-fibrosis drugs1R33HL154117-01Zhao, RuogangSTATE UNIVERSITY OF NEW YORK AT BUFFALO, NYFirst-year cost $460,967Study section ZHL1
FY2020Development of a next-generation glycomics platform to enable glycan structure analyses for precision medicine1R33HL154123-01Gundry, Rebekah L.UNIVERSITY OF NEBRASKA MEDICAL CENTER, NEFirst-year cost $458,564Study section ZHL1
FY2020Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic Interventions1R33HL154103-01Florova, GalinaIdell, StevenKomissarov, AndreyUNIVERSITY OF TEXAS HLTH CTR AT TYLER, TXFirst-year cost $441,000Study section ZHL1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-16-0.3.5. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-HL-20-022: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) | ConductScience ScienceDex